Wearable devices for improving medication adherence in older adults with chronic conditions: A systematic review.

Int J Med InformMay 28, 2026 (epub)
Clinical ResearchGeriatricsPreventive Medicine / Public Health

Sofia Taborri, Erika Renzi, Azzurra Massimi et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the impact of wearable devices on medication adherence in adults aged 65 and older with chronic conditions. Among nine studies analyzed, seven reported significant improvements in adherence compared to control groups. The review suggests that wearable devices, particularly when combined with reminder systems, can enhance medication adherence in this population.

Key findings

  • Seven of nine studies showed statistically significant improvements in medication adherence with wearable devices.
  • Positive effects were noted in 3 out of 4 smartwatch interventions.
  • Three out of four wearable blood pressure monitor interventions also demonstrated significant adherence improvements.
  • The ECG-based intervention did not show significant between-group differences.

Why it matters

Improving medication adherence in older adults is crucial for reducing complications, hospital readmissions, and healthcare costs. Wearable devices may provide a practical solution to enhance adherence through continuous monitoring and reminders.

Source

PubMed · PMID 42248063

Published in Int J Med Inform. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Geriatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.